Looking Forward to a GREAT 2020, page-220

As @Dyoresearch posts above, Wikipedia describes CBG as "the non-acidic form of CBG acid, the parent molecule from which other cannabinoids are synthesized". I would not be at all surprised, however, to see others refer to it as a CBD analog, as per the following extract from this published 2017 medical paper:

"Another minor component of Cannabis sativa is cannabigerol (CBG) (Gaoni and Mechoulam, 1971). Structurally, CBG can be considered the cyclohexenyl-opened analog of CBD. Different therapeutic applications have been proposed for CBG, more recently CBG has been shown to have antibacterial action (Appendino et al., 2008), antidepressant-like action (El-Alfy et al., 2010), and anti-inflammatory properties for bowel disease (Borrelli et al., 2013)."

Therefore Botanix, having produced its own synthetic cannabidiol for its trials, could perhaps have synthesized some CBG due to its known antibacterial action. I would not find it necessary for Botanix to disclose this if it was part of its IP. Does it complicate patent ownership?